Carolyn M. Rucci

Executive

Akebia Therapeutics, Inc.

Insider activity · 24 months0 buys3 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 3 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (3 ops.)

€82k

Latest filing published 04 Feb 2026 for Akebia Therapeutics, Inc., €30k.

Filing timeline

BuySale

Carolyn M. Rucci

Insider track record

Disclosed buys

Disclosed sells

Signal history

Carolyn M. Rucci: trading record in brief

Carolyn M. Rucci is a declared insider of Akebia Therapeutics, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 30 January 2026 to 2 February 2026, the count stands at 4 filings.

The open-market record consists of 3 sales worth €82k, with no purchase. The rest of the record consists of 1 share grant.

Most recently, on 4 February 2026, the filings show an open-market sale worth €30k in Akebia Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.